1.Role of palliative care in improving the symptoms of dyspnea and negative emotions in patients with lung cancer
Linan ZHANG ; Juan ZHOU ; Jizi LIU
Modern Clinical Nursing 2015;(6):40-43
Objective To explore the effect of palliative care on dyspnea and negative emotions in patients with lung cancer. Methods According to admission sequence, 100 lung cancer patients with dyspnea received palliative care both for 2 weeks. The differences of dyspnea and negative emotions before and after intervention were observed. Result After the intervention, the degree of dyspnea and negative emotions were significantly lower than that before (P<0.05). Conclusion The palliative care not only makes lung cancer patients physiologically and psychologically happy , but also lowers the level of anxiety and negative emotions , relieves dyspnea, and thus improves the quality of life.
2.Pharmacokinetic and pharmacodynamic study of triptolide-loaded liposome hydrogel patch under microneedles on rats with collagen-induced arthritis.
Gui CHEN ; Baohua HAO ; Dahong JU ; Meijie LIU ; Hongyan ZHAO ; Zhongping DU ; Jizi XIA
Acta Pharmaceutica Sinica B 2015;5(6):569-576
Triptolide (TP), a major active component of Tripterygium wilfordii Hook.F. (TWHF), is used to treat rheumatoid arthritis (RA). However, it has a narrow therapeutic window due to its serious toxicities. To increase the therapeutic index, a new triptolide-loaded transdermal delivery system, named triptolide-loaded liposome hydrogel patch (TP-LHP), has been developed. In this paper, we used a micro-needle array to deliver TP-LHP to promote transdermal absorption and evaluated this treatment on the pharmacokinetics and pharmacodynamics of TP-LHP in a rat model of collagen-induced arthritis (CIA). The pharmacokinetic results showed that transdermal delivery of microneedle TP-LHP yielded plasma drug levels which fit a one-compartment open model. The relationship equation between plasma concentration and time was C=303.59×(e(-0.064t) -e(-0.287t) ). The results of pharmacodynamic study demonstrated that TP-LHP treatment mitigated the degree of joint swelling and suppressed the expressions of fetal liver kinase-1, fetal liver tyrosine kinase-4 and hypoxia-inducible factor-1α in synovium. Other indicators were also reduced by TP-LHP, including hyperfunction of immune, interleukin-1β and interleukin-6 levels in serum. The therapeutic mechanism of TP-LHP might be regulation of the balance between Th1 and Th2, as well as inhibition of the expression and biological effects of vascular endothelial growth factor.